ROSEN Law Firm Urges OTLK Investors to Act Before Deadline in Securities Class Action

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Attention is drawn towards shareholders of Outlook Therapeutics, Inc. OTLK, a biopharmaceutical company, as they are reminded of the upcoming deadline to secure legal counsel. The call to action comes from ROSEN, a globally recognized investor rights law firm, which emphasizes the January 2nd deadline for investors who suffered losses in OTLK securities during the December 29, 2022, to August 29, 2023 class period.

Understanding the Class Action

The class-action lawsuit filed against Outlook Therapeutics alleges that the company made materially false and/or misleading statements, as well as failed to disclose pertinent information to investors. The case claims that investors suffered damages as a result of the company's oversight. The legal firm is advocating for affected investors to come forward and enlist their counsel to potentially recover their lost investments.

Outlook Therapeutics at a Glance

Outlook Therapeutics, Inc., operating under the stock ticker OTLK, is based in Cranbury, New Jersey. The company is in the late-stage biopharmaceutical sector, focusing on the development and commercialization of monoclonal antibodies for various ophthalmic indications. The importance of this phase in the company's operation cannot be understated, as shareholder investments hinge on the successful advancement of its therapeutic lineup.

The Critical Deadline

The warning issued pertains to the critical January 2nd deadline, appointed for investors who have encountered financial shortcomings due to their stake in OTLK. ROSEN Law Firm underscores this date as a pivotal moment for shareholders to take decisive action to protect their assets and seek reparations for any wrongdoing they may have been subjected to as a result of the company's conduct.

Investment, Legal, Deadline